Such patients with progressive metastatic disease, despite having received currently available first- and second-line chemotherapies, and who exhibit the tumor-specific expression of the epidermal growth factor receptor (EGFR) are eligible to receive third-line treatment with irinotecan and cetuximab. The gene discussed is EGFR; the disease is metastatic neoplasm.